Kenneth A Freedberg

List of Publications by Year
in descending order

117	4,729	136740	106150
papers	citations	32 h-index	65 g-index

123	123	123	6021
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic point-of-care tests in resource-limited settings. Lancet Infectious Diseases, The, 2014, 14, 239-249.	4.6	525
2	Expanded Screening for HIV in the United States â€" An Analysis of Cost-Effectiveness. New England Journal of Medicine, 2005, 352, 586-595.	13.9	504
3	The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal of Medicine, 2001, 344, 824-831.	13.9	469
4	Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. JAMA Network Open, 2019, 2, e187621.	2.8	220
5	The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA - Journal of the American Medical Association, 1998, 279, 130.	3.8	218
6	Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness. Annals of Internal Medicine, 2001, 134, 440.	2.0	215
7	Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal of Medicine, 2013, 369, 1715-1725.	13.9	122
8	A Randomized Controlled Trial to Enhance Antiretroviral Therapy Adherence in Patients with a History of Alcohol Problems. Antiviral Therapy, 2005, 10, 83-93.	0.6	100
9	Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Internal Medicine, 2017, 177, 1613.	2.6	99
10	Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. American Journal of Medicine, 2003, 115, 632-641.	0.6	97
11	The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care, 2015, 53, 293-301.	1.1	94
12	Waiting for Certainty on Covid-19 Antibody Tests â€" At What Cost?. New England Journal of Medicine, 2020, 383, e37.	13.9	80
13	HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antiviral Therapy, 2009, 14, 523-531.	0.6	79
14	Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. The Lancet Global Health, 2021, 9, e120-e129.	2.9	71
15	College Campuses and COVID-19 Mitigation: Clinical and Economic Value. Annals of Internal Medicine, 2021, 174, 472-483.	2.0	64
16	The Independent Effect of Highly Active Antiretroviral Therapy on Severe Opportunistic Disease Incidence and Mortality in HIV-Infected Adults in CÃ´te D'Ivoire. Antiviral Therapy, 2007, 12, 543-551.	0.6	60
17	Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts. Clinical Infectious Diseases, 2021, 73, e2908-e2917.	2.9	52
18	Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. Aids, 2007, 21, S117-S128.	1.0	48

#	Article	IF	Citations
19	The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Medicine, 2014, 11, e1001725.	3.9	48
20	Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic. JAMA Network Open, 2020, 3, e2028195.	2.8	48
21	Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults. American Journal of Public Health, 2001, 91, 1456-1463.	1.5	46
22	Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, S113-S118.	0.9	46
23	Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. PLoS ONE, 2014, 9, e85197.	1.1	45
24	WHO 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in Zimbabwe: Modeling Clinical Outcomes in Infants and Mothers. PLoS ONE, 2011, 6, e20224.	1.1	41
25	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 60, 1102-1110.	2.9	41
26	Comparative Pricing of Branded Tenofovir Alafenamideâ€“Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarateâ€“Emtricitabine for HIV Preexposure Prophylaxis. Annals of Internal Medicine, 2020, 172, 583-590.	2.0	40
27	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. Journal of Infectious Diseases, 2016, 213, 1523-1531.	1.9	39
28	Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for Indiaâ€™s public sector. PLoS ONE, 2019, 14, e0218890.	1.1	37
29	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. Annals of Internal Medicine, 2022, 175, 479-489.	2.0	37
30	Lifetime Cost of HIV Care in France during the Era of Highly Active Antiretroviral Therapy. Antiviral Therapy, 2002, 7, 257-266.	0.6	37
31	The Anticipated Clinical and Economic Effects of 90â€“90â€“90 in South Africa. Annals of Internal Medicine, 2016, 165, 325.	2.0	36
32	Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV,the, 2019, 6, e182-e190.	2.1	36
33	Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Affairs, 2017, 36, 2142-2150.	2.5	34
34	Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. Aids, 2015, 29, 1247-1259.	1.0	33
35	Finding HIV in Hard to Reach Populations: Mobile HIV Testing and Geospatial Mapping in Umlazi Township, Durban, South Africa. AIDS and Behavior, 2015, 19, 1888-1895.	1.4	33
36	Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. The Lancet Global Health, 2019, 7, e200-e208.	2.9	32

#	Article	IF	Citations
37	Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. PLoS ONE, 2013, 8, e84173.	1.1	32
38	Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. Nature Communications, 2021, 12, 6238.	5.8	31
39	The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. PLoS Medicine, 2017, 14, e1002446.	3.9	30
40	Validation and Calibration of a Computer Simulation Model of Pediatric HIV Infection. PLoS ONE, 2013, 8, e83389.	1.1	29
41	Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2001, 32, 783-793.	2.9	26
42	The costâ€effectiveness of HIV preâ€exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Journal of the International AIDS Society, 2018, 21, e25096.	1.2	24
43	The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. Journal of Adolescent Health, 2018, 62, 22-28.	1.2	23
44	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. International Journal of Drug Policy, 2019, 72, 160-168.	1.6	23
45	The Linkage Outcomes of a Large-scale, Rapid Transfer of HIV-infected Patients From Hospital-based to Community-based Clinics in South Africa. Open Forum Infectious Diseases, 2014, 1, ofu058.	0.4	22
46	Clinical outcomes of HIV care delivery models in the US: a systematic review. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1215-1222.	0.6	22
47	Foreign-born status as a predictor of engagement in HIV care in a large US metropolitan health system. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 244-251.	0.6	22
48	Effect of PEPFAR funding policy change on HIV service delivery in a large HIV care and treatment network in Nigeria. PLoS ONE, 2019, 14, e0221809.	1.1	22
49	Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort. BMC Infectious Diseases, 2019, 19, 14.	1.3	22
50	Improving Participation in HIV Clinical Trials: Impact of a Brief Intervention. HIV Clinical Trials, 2001, 2, 205-212.	2.0	21
51	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. PLoS ONE, 2014, 9, e113031.	1.1	21
52	Development, Calibration and Performance of an HIV Transmission Model Incorporating Natural History and Behavioral Patterns: Application in South Africa. PLoS ONE, 2014, 9, e98272.	1.1	20
53	Age Matters: Increased Risk of Inconsistent HIV Care and Viremia Among Adolescents and Young Adults on Antiretroviral Therapy in Nigeria. Journal of Adolescent Health, 2016, 59, 298-304.	1.2	20
54	Costâ€“effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics, 2015, 16, 2007-2018.	0.6	19

#	Article	IF	Citations
55	Survival benefits of antiretroviral therapy in Brazil: a modelâ€based analysis. Journal of the International AIDS Society, 2016, 19, 20623.	1.2	19
56	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Annals of Internal Medicine, 2017, 167, 618.	2.0	18
57	The costâ€effectiveness and budgetary impact of a dolutegravirâ€based regimen as firstâ€line treatment of <scp>HIV</scp> infection in India. Journal of the International AIDS Society, 2018, 21, e25085.	1.2	17
58	Cost-Effectiveness of Prenatal Screening for Postpartum Thyroiditis. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 649-658.	1.7	16
59	Medication Possession Ratio: Predicting and Decreasing Loss to Follow-Up in Antiretroviral Treatment Programs in CÃ´te d'Ivoire. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S34-S39.	0.9	16
60	Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil. AIDS Research and Therapy, 2014, 11, 29.	0.7	14
61	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infectious Diseases, 2017, 4, ofw266.	0.4	14
62	Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 148-156.	0.9	14
63	Optimal Frequency of Cd4 Cell Count and HIV Rna Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 41-52.	0.6	14
64	High rates of unplanned interruptions from HIV care early after antiretroviral therapy initiation in Nigeria. BMC Infectious Diseases, 2015, 15, 397.	1.3	13
65	Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, S12-S21.	0.9	12
66	Point-of-Care CD4 Testing to Inform Selection of Antiretroviral Medications in South African Antenatal Clinics: A Cost-Effectiveness Analysis. PLoS ONE, 2015, 10, e0117751.	1.1	12
67	Cost-Effectiveness of Genotype Testing for Primary Resistance in Brazil. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 152-161.	0.9	11
68	Clinic-Based Urinary Lipoarabinomannan as a Biomarker of Clinical Disease Severity and Mortality Among Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Infected Adults in South Africa. Open Forum Infectious Diseases, 2017, 4, ofx167.	0.4	11
69	Optimal breastfeeding durations for HIVâ€exposed infants: the impact of maternal <scp>ART</scp> use, infant mortality and replacement feeding risk. Journal of the International AIDS Society, 2018, 21, e25107.	1.2	10
70	Using Observational Data to Calibrate Simulation Models. Medical Decision Making, 2018, 38, 212-224.	1.2	10
71	Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa. PLoS ONE, 2019, 14, e0225104.	1.1	10
72	Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2077-e2085.	2.9	10

#	Article	IF	Citations
73	Prenatal Transmission of Syphilis and Human Immunodeficiency Virus in Brazil: Achieving Regional Targets for Elimination. Open Forum Infectious Diseases, 2015, 2, ofv073.	0.4	9
74	Using national laboratory data to assess cumulative frequency of linkage after transfer to communityâ€based HIV clinics in South Africa. Journal of the International AIDS Society, 2019, 22, e25326.	1.2	9
75	Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries. Journal of Infectious Diseases, 2022, 226, 1887-1896.	1.9	9
76	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. HIV Clinical Trials, 2012, 13, 1-10.	2.0	8
77	Individualizing the WHO HIV and infant feeding guidelines. Aids, 2014, 28, S287-S299.	1.0	7
78	Impact of Unplanned Care Interruption on CD4 Response Early After ART Initiation in a Nigerian Cohort. Journal of the International Association of Providers of AIDS Care, 2017, 16, 98-104.	0.6	7
79	High Medication Possession Ratios Associated With Greater Risk of Virologic Failure Among Youth Compared With Adults in a Nigerian Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 322-328.	0.9	7
80	â€œCureâ€•Versus â€œClinical Remissionâ€: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication. AIDS and Behavior, 2020, 24, 2054-2061.	1.4	7
81	Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases, 2021, 73, e1927-e1935.	2.9	7
82	Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. BMJ Open, 2020, 10, e032579.	0.8	7
83	The Challenges of Parameterizing Direct Effects in Individual-Level Simulation Models. Medical Decision Making, 2020, 40, 106-111.	1.2	7
84	The impact of user fees on uptake of HIV services and adherence to HIV treatment: Findings from a large HIV program in Nigeria. PLoS ONE, 2020, 15, e0238720.	1.1	7
85	The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. Journal of Virus Eradication, 2015, 1, 245-249.	0.3	7
86	Do not forget the children: a modelâ€based analysis on the potential impact of COVIDâ€19â€associated interruptions in paediatric HIV prevention and care. Journal of the International AIDS Society, 2022, 25, e25864.	1.2	7
87	Performance Measures for Guidelines on Preventing Opportunistic Infections in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2000, 30, S85-S93.	2.9	6
88	The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials. HIV Clinical Trials, 2014, 15, 185-198.	2.0	6
89	Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. Clinical Infectious Diseases, 2017, 64, 1612-1614.	2.9	6
90	Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County. Open Forum Infectious Diseases, 2019, 6, ofz537.	0.4	6

#	Article	IF	Citations
91	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. MDM Policy and Practice, 2020, 5, 238146832093289.	0.5	6
92	Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161). JMIR Research Protocols, 2019, 8, e9898.	0.5	6
93	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. Journal of Virus Eradication, 2019, 5, 109-115.	0.3	6
94	The patient-centered medical home: a reality for HIV care in Nigeria. International Journal for Quality in Health Care, 2017, 29, 654-661.	0.9	5
95	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in CÃ´te dâ€™Ivoire: A model-based analysis. PLoS ONE, 2019, 14, e0219068.	1.1	5
96	A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. Journal of Biomedical Informatics, 2020, 107, 103475.	2.5	5
97	Optimizing infant HIV diagnosis with additional screening at immunization clinics in three subâ€Saharan African settings: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2021, 24, e25651.	1.2	5
98	Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. AIDS and Behavior, 2021, 25, 2973-2984.	1.4	5
99	Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. Lancet HIV,the, 2022, 9, e585-e594.	2.1	5
100	HIV Testing After a First Positive Rapid Diagnostic Test: A Role for Nucleic Acid Testing?. Open Forum Infectious Diseases, 2018, 5, ofy170.	0.4	4
101	Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness. Clinical Infectious Diseases, 2018, 67, 719-726.	2.9	4
102	Comparative Pricing of Branded Tenofovir Alafenamideâ€“Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarateâ€“Emtricitabine for HIV Preexposure Prophylaxis. Annals of Internal Medicine, 2020, 173, 507-508.	2.0	4
103	HIV testing rates, prevalence, and knowledge among outpatients in Durban, South Africa: Time trends over four years. International Journal of STD and AIDS, 2015, 26, 704-709.	0.5	3
104	Psychological Distress Increases 30-Fold Among People with HIV in the First Year on ART in Nigeriaâ€”a Call for Integrated Mental Health Services. International Journal of Behavioral Medicine, 2023, 30, 38-48.	0.8	3
105	The Private Side of the Professional Man. Journal of Investigative Dermatology, 2006, 126, 533-535.	0.3	2
106	Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India. AIDS Research and Human Retroviruses, 2018, 34, 486-497.	0.5	2
107	HIV testing in a large community health center serving a multi-cultural patient population: A qualitative study of providers. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1585-1592.	0.6	2
108	Cost of an HIV Medical Care Coordination Program in Los Angeles County. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e15-e17.	0.9	2

#	Article	IF	Citations
109	Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South Africa. Open Forum Infectious Diseases, 2022, 9, ofab603.	0.4	2
110	Clearance of Hepatitis B e Antigen in Untreated Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2022, 226, 1761-1770.	1.9	2
111	The cost-effectiveness of a resilience-based psychosocial intervention for HIV prevention among men who have sex with men in India. Aids, 2022, Publish Ahead of Print, .	1.0	1
112	1551The Patient-Centered Medical Home: A Reality for HIV Care in Nigeria. Open Forum Infectious Diseases, 2014, 1, S412-S413.	0.4	0
113	Misinterpretation of HIV Preexposure Prophylaxis Findings. Clinical Infectious Diseases, 2014, 59, 139-141.	2.9	0
114	1269. HIV Testing in a Large Community Health Center Serving a Multi-cultural Population: A Qualitative Study of Providers. Open Forum Infectious Diseases, 2018, 5, S387-S387.	0.4	0
115	Comparative Effectiveness of Interventions to Improve the HIV Continuum of Care and HIV Preexposure Prophylaxis in Kenya: A Model-Based Analysis. Journal of Infectious Diseases, 2020, , .	1.9	0
116	Evaluating Point-of-Care Nucleic Acid Tests in Adult Human Immunodeficiency Virus Diagnostic Strategies: A CÃ´te dâ€™Ivoire Modeling Analysis. Open Forum Infectious Diseases, 2021, 8, ofab225.	0.4	0
117	Impact of Expanded HIV Screening. Annals of Internal Medicine, 2007, 147, 146.	2.0	0